Implementation of Electronic Adherence Monitors and Associated Interventions for Routine HIV Antiretroviral Therapy in Uganda: Promising Findings.

Africa HIV SMS intervention electronic adherence monitoring implementation science

Journal

Frontiers in digital health
ISSN: 2673-253X
Titre abrégé: Front Digit Health
Pays: Switzerland
ID NLM: 101771889

Informations de publication

Date de publication:
2022
Historique:
received: 18 03 2022
accepted: 24 06 2022
entrez: 8 8 2022
pubmed: 9 8 2022
medline: 9 8 2022
Statut: epublish

Résumé

High, sustained adherence is critical for achieving the individual and public health benefits of HIV antiretroviral therapy (ART). Electronic monitors provide detailed adherence information and can enable real-time interventions; however, their use to date has largely been confined to research. This pilot study (NCT03825952) sought to understand feasibility and acceptability a relatively low-cost version of this technology and associated interventions for routine ART delivery in sub-Saharan Africa. We provided two ART clinics in rural, southwestern Uganda with electronic adherence monitors for data-informed counseling as well as optional SMS messages to clients and/or social supporters (daily or triggered by missed or delayed doses) and/or an alarm. Clinic and ART client experiences were observed for 3 months per client, including time and motion studies. Qualitative interviews among clients, clinicians, and healthcare administrators were informed by the Consolidated Framework for Implementation Research. Fifty-one ART clients were enrolled; 57% were male and the median age was 34 years. Choice of associated intervention varied among participants. The median number of visits during follow-up was two per client. Counselors reviewed the adherence data with 90% of clients at least once; 67% reviewed data at all visits. Average adherence was 94%; four clients had adherence gaps >1 week. Acceptability was high; all but one client found the monitor "very useful" and all found SMS "very useful." Clinic visits among clients with the intervention lasted 4 min longer on average than those in standard care. The monitors and daily SMS generally functioned well, although excess SMS were triggered, primarily due to cellular network delays. Overall, participants felt the technology improved adherence, clinic experiences, and clinician-client relationships. Few worried about stigma and privacy. Cost was a concern for implementation, particularly at scale. We successfully implemented a relatively low-cost electronic ART adherence monitor and associated interventions for routine care in rural Uganda. Feasibility and acceptability were generally high, and individuals were identified who could benefit from adherence support. Future work should involve longitudinal follow-up of diverse populations, clinical outcomes, and detailed cost-effectiveness analysis to help drive policy decisions around the uptake of this technology for routine clinical care. identifier: NCT03825952.

Sections du résumé

Background UNASSIGNED
High, sustained adherence is critical for achieving the individual and public health benefits of HIV antiretroviral therapy (ART). Electronic monitors provide detailed adherence information and can enable real-time interventions; however, their use to date has largely been confined to research. This pilot study (NCT03825952) sought to understand feasibility and acceptability a relatively low-cost version of this technology and associated interventions for routine ART delivery in sub-Saharan Africa.
Methods UNASSIGNED
We provided two ART clinics in rural, southwestern Uganda with electronic adherence monitors for data-informed counseling as well as optional SMS messages to clients and/or social supporters (daily or triggered by missed or delayed doses) and/or an alarm. Clinic and ART client experiences were observed for 3 months per client, including time and motion studies. Qualitative interviews among clients, clinicians, and healthcare administrators were informed by the Consolidated Framework for Implementation Research.
Results UNASSIGNED
Fifty-one ART clients were enrolled; 57% were male and the median age was 34 years. Choice of associated intervention varied among participants. The median number of visits during follow-up was two per client. Counselors reviewed the adherence data with 90% of clients at least once; 67% reviewed data at all visits. Average adherence was 94%; four clients had adherence gaps >1 week. Acceptability was high; all but one client found the monitor "very useful" and all found SMS "very useful." Clinic visits among clients with the intervention lasted 4 min longer on average than those in standard care. The monitors and daily SMS generally functioned well, although excess SMS were triggered, primarily due to cellular network delays. Overall, participants felt the technology improved adherence, clinic experiences, and clinician-client relationships. Few worried about stigma and privacy. Cost was a concern for implementation, particularly at scale.
Conclusion UNASSIGNED
We successfully implemented a relatively low-cost electronic ART adherence monitor and associated interventions for routine care in rural Uganda. Feasibility and acceptability were generally high, and individuals were identified who could benefit from adherence support. Future work should involve longitudinal follow-up of diverse populations, clinical outcomes, and detailed cost-effectiveness analysis to help drive policy decisions around the uptake of this technology for routine clinical care.
Clinical Trial Registration UNASSIGNED
identifier: NCT03825952.

Identifiants

pubmed: 35937420
doi: 10.3389/fdgth.2022.899643
pmc: PMC9354256
doi:

Banques de données

ClinicalTrials.gov
['NCT03825952']

Types de publication

Case Reports

Langues

eng

Pagination

899643

Informations de copyright

Copyright © 2022 Haberer, Baijuka, Tumuhairwe, Tindimwebwa, Tinkamanyire, Tuhanamagyezi, Musoke, Garrison, DelSignore, Musinguzi and Asiimwe.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Health Res Policy Syst. 2011 Jan 31;9:6
pubmed: 21276274
AIDS Behav. 2013 Jan;17(1):319-28
pubmed: 23229338
J Gen Intern Med. 2009 Feb;24(2):189-97
pubmed: 19031037
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):495-502
pubmed: 26218411
AIDS Care. 2012;24(11):1448-52
pubmed: 22670758
AIDS. 2016 May 15;30(8):1295-300
pubmed: 26760452
PLoS One. 2016 Dec 15;11(12):e0167654
pubmed: 27977702
Int J Gen Med. 2019 Nov 06;12:395-403
pubmed: 31819592
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):542-545
pubmed: 26990822
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21648
pubmed: 28770597
J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S14-8
pubmed: 17525686
AIDS. 2017 Mar 13;31(5):719-726
pubmed: 28225450
AIDS Behav. 2013 Jan;17(1):434-43
pubmed: 22246514
J Acquir Immune Defic Syndr. 2021 May 1;87(1):688-692
pubmed: 33470727
AIDS Behav. 2019 May;23(5):1306-1314
pubmed: 30377982
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
BMC Public Health. 2014 Oct 04;14:1035
pubmed: 25280535
JMIR Mhealth Uhealth. 2020 Jul 31;8(7):e16634
pubmed: 32735220
BMC Psychol. 2015 Sep 16;3:32
pubmed: 26376626
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):386-92
pubmed: 26110445
J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):551-9
pubmed: 25886927
Soc Sci Med. 2011 Dec;73(12):1717-24
pubmed: 22019367
J Stud Alcohol. 2005 May;66(3):428-32
pubmed: 16047534
Curr HIV/AIDS Rep. 2020 Aug;17(4):301-314
pubmed: 32424549
J Med Internet Res. 2020 Sep 10;22(9):e18038
pubmed: 32687473

Auteurs

Jessica E Haberer (JE)

Center for Global Health, Massachusetts General Hospital, Boston, MA, United States.
Department of Medicine, Harvard Medical School, Boston, MA, United States.

Robert Baijuka (R)

Kabwohe Clinical Research Centre, Kabwohe, Uganda.

John Bosco Tumuhairwe (JB)

Kabwohe Clinical Research Centre, Kabwohe, Uganda.

Edna B Tindimwebwa (EB)

Kabwohe Clinical Research Centre, Kabwohe, Uganda.

James Tinkamanyire (J)

Kabwohe Clinical Research Centre, Kabwohe, Uganda.

Ellyk Tuhanamagyezi (E)

Kabwohe Clinical Research Centre, Kabwohe, Uganda.

Lawrence Musoke (L)

Kabwohe Clinical Research Centre, Kabwohe, Uganda.

Lindsey E Garrison (LE)

Center for Global Health, Massachusetts General Hospital, Boston, MA, United States.

Marisa DelSignore (M)

Center for Global Health, Massachusetts General Hospital, Boston, MA, United States.

Nicholas Musinguzi (N)

Center for Global Health, Massachusetts General Hospital, Boston, MA, United States.

Stephen Asiimwe (S)

Center for Global Health, Massachusetts General Hospital, Boston, MA, United States.
Kabwohe Clinical Research Centre, Kabwohe, Uganda.

Classifications MeSH